Use of trimetazidine as a hepatoprotective medicine in prevention and treatment of liver diseases and conditions

Abstract

This present invention discloses a new use of trimetazidine as a hepatoprotective drug in prevention and treatment of liver diseases, wherein trimetazidine is capable of inhibiting activation of resting T lymphocytes to activated lymphocytes, reducing release of cytokines, and reducing the hepatocyte injury caused by the immune system; capable of inhibiting fatty acid metabolism in hepatocytes and optimizing energy process in hepatocytes; and capable of maintaining normal function of mitochondrial permeability transition pores and reducing hepatocyte apoptosis. Clinical research and trial results suggest that, when administered to patients suffering from liver diseases and conditions, trimetazidine is capable of providing significant hepatoprotective function, and effectively decreasing transaminase levels (including alanine aminotransferase, aspartate transaminase, etc.), with such features as shortening the course of disease, reducing the mortality rate, easy and safe use, and low treatment cost. Trimetazidine is eliminated unchanged mainly through urine, with the elimination half-life of approximately 6 hours, and without hepatic metabolism. Therefore, trimetazidine has minimal liver toxicity, while having significant hepatoprotective effect.